RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 10 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Non-small cell lung cancer (NSCLC) confirmed by histological and/or cytological examination. Invasive subtypes are required for adenocarcinomas.

    Inclusion criterion 1

    Stage IA or IB after surgery based on pathological TNM8 staging criteria established by the International Union Against Cancer/American Joint Committee on Cancer (8th Edition).

    Inclusion criterion 2

  3. Complete recovery from surgery with no evidence of disease progression within 2 weeks prior to the first treatment decision.

    Inclusion criterion 4

    Previous use of any traditional Chinese medicine with anti-tumor properties, or use of such medicine within 2 weeks prior to surgery.

    Exclusion criterion 6

    Blood transfusion within 2 weeks prior to and during the surgery.

    Exclusion criterion 20

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

    Inclusion criterion 5

  5. Absolute neutrophil count ≥1.5×10\^9/L

    Inclusion criterion 8

    Platelet count ≥100×10\^9/L

    Inclusion criterion 9

    Hemoglobin ≥90 g/L

    Inclusion criterion 10

    ALT ≤2.5× upper limit of normal (ULN)

    Inclusion criterion 11

    AST ≤2.5×ULN

    Inclusion criterion 12

    Total Bilirubin (TBL) ≤1.5×ULN Renal function: Creatinine level ≤1.25×ULN, or creatinine clearance ≥60 mL/min (measured or calculated using the Cockcroft-Gault formula).

    Inclusion criterion 13

  6. History of other malignancies within the past 5 years, with the exception of the following:

    Exclusion criterion 7

    Other malignancies fully cured by surgery with a disease-free survival of more than 10 years

    Exclusion criterion 8

  7. Participants regardless of sex must agree to use effective contraception during the study period and for 3 months following treatment completion.

    Inclusion criterion 16

    Pregnant or breastfeeding females.

    Exclusion criterion 22

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06709274, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Non-small cell lung cancer (NSCLC) confirmed by histological and/or cytological examination. Invasive subtypes are required for adenocarcinomas.
  • Stage IA or IB after surgery based on pathological TNM8 staging criteria established by the International Union Against Cancer/American Joint Committee on Cancer (8th Edition).
  • Completely surgical resection (R0) of the primary NSCLC via lobectomy, segmentectomy, or sleeve lobectomy. The gross tumor must be entirely removed, and all surgical margins of the excised tumor must be negative.
  • Complete recovery from surgery with no evidence of disease progression within 2 weeks prior to the first treatment decision.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  • Minimum life expectancy of ≥12 weeks.
  • Demonstrate adequate organ function, including:

Hematological parameters:

  • Absolute neutrophil count ≥1.5×10\^9/L
  • Platelet count ≥100×10\^9/L
  • Hemoglobin ≥90 g/L

Liver function:

  • ALT ≤2.5× upper limit of normal (ULN)
  • AST ≤2.5×ULN
  • Total Bilirubin (TBL) ≤1.5×ULN Renal function: Creatinine level ≤1.25×ULN, or creatinine clearance ≥60 mL/min (measured or calculated using the Cockcroft-Gault formula).
  • Male or female, age between 18 and 75 years.
  • Written informed consent must be obtained from the subject or their legal representative.
  • Participants regardless of sex must agree to use effective contraception during the study period and for 3 months following treatment completion.
  • Willingness and ability to comply with visit schedules, treatment plans, and laboratory assessments.

Exclusion Criteria:

  • Histopathologically confirmed small cell carcinoma components.
  • Presence of multiple pulmonary nodules.
  • Incomplete resections (R1/R2) or resections via bilateral lobectomy, pneumonectomy, or wedge resection.
  • A history of any systemic anti-tumor treatment, including but not limited to surgery, neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
  • Significant allergies to any targeted drugs, immunotherapies, or chemotherapy agents used in the study.
  • Previous use of any traditional Chinese medicine with anti-tumor properties, or use of such medicine within 2 weeks prior to surgery.
  • History of other malignancies within the past 5 years, with the exception of the following:
  • Other malignancies fully cured by surgery with a disease-free survival of more than 10 years
  • Curable basal cell carcinoma of the skin
  • Bladder carcinoma in situ
  • Cervical carcinoma in situ
  • History of interstitial lung disease, drug-induced interstitial lung disease, radiation-induced pneumonia requiring steroid treatment, or any evidence of clinically active interstitial lung disease.
  • Active hepatitis B, defined as HBsAg positive with an HBV-DNA copy number exceeding the ULN established by the study center, accompanied by abnormal liver function, or requiring treatment as evaluated by the investigator.
  • Presence of any unstable systemic disease, including but not limited to active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the past 3 months, serious arrhythmias that requires medication, liver disease, kidney disease, or metabolic disorders.
  • Evidence of any other diseases, neurological or metabolic disorders, or physical exam or laboratory findings that may suggest contraindications for the investigational drug, or a high risk for treatment-related complications.
  • Any of the following cardiac conditions:
  • Resting ECG QT interval (QTc) > 470 msec.
  • Significant abnormalities in rhythm, conduction, or morphology on resting ECG, including complete left bundle branch block, third-degree atrioventricular block, or second-degree atrioventricular block
  • Factors increasing the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death in a first-degree relative under the age of 40, or use of medications known to prolong QT interval.
  • Blood transfusion within 2 weeks prior to and during the surgery.
  • History of alcohol or drug abuse.
  • Pregnant or breastfeeding females.
  • Any other factors that the investigator deems may affect the progress of the study or compromise the trial data

Quoted from ClinicalTrials.gov, NCT06709274, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06709274, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06709274